<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/353" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/353/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/353/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_353"><akn:num>353</akn:num><akn:heading>Exemptions and consideration for certain drugs, devices, and biological products</akn:heading><akn:content><akn:p>§ 353. Exemptions and consideration for certain drugs, devices, and biological products(a) Regulations for goods to be processed, labeled, or repacked elsewhereThe Secretary is directed to promulgate regulations exempting from any labeling or packaging requirement of this chapter drugs and devices which are, in accordance with the practice of the trade, to be processed, labeled, or repacked in substantial quantities at establishments other than those where originally processed or packed, on condition that such drugs and devices are not adulterated or misbranded under the provisions of this chapter upon removal from such processing, labeling, or repacking establishment.


(b) Prescription by physician; exemption from labeling and prescription requirements; misbranded drugs; compliance with narcotic and marihuana laws(1) A drug intended for use by man which—(A) because of its toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use, is not safe for use except under the supervision of a practitioner licensed by law to administer such drug; or

(B) is limited by an approved application under section 355 of this title to use under the professional supervision of a practitioner licensed by law to administer such drug;


shall be dispensed only (i) upon a written prescription of a practitioner licensed by law to administer such drug, or (ii) upon an oral prescription of such practitioner which is reduced promptly to writing and filed by the pharmacist, or (iii) by refilling any such written or oral prescription if such refilling is authorized by the prescriber either in the original prescription or by oral order which is reduced promptly to writing and filed by the pharmacist. The act of dispensing a drug contrary to the provisions of this paragraph shall be deemed to be an act which results in the drug being misbranded while held for sale.

(2) Any drug dispensed by filling or refilling a written or oral </akn:p></akn:content><akn:subsection eId="subsec_353_a"><akn:num>(a)</akn:num><akn:heading>Regulations for goods to be processed, labeled, or repacked elsewhere</akn:heading><akn:content><akn:p>(a) Regulations for goods to be processed, labeled, or repacked elsewhere The Secretary is directed to promulgate regulations exempting from any labeling or packaging requirement of this chapter drugs and devices which are, in accordance with the practice of the trade, to be processed, labeled, or repacked in substantial quantities at establishments other than those where originally processed or packed, on condition that such drugs and devices are not adulterated or misbranded under the provisions of this chapter upon removal from such processing, labeling, or repacking establishment.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_353_b"><akn:num>(b)</akn:num><akn:heading>Prescription by physician; exemption from labeling and prescription requirements; misbranded drugs; compliance with narcotic and marihuana laws</akn:heading><akn:content><akn:p>(b) Prescription by physician; exemption from labeling and prescription requirements; misbranded drugs; compliance with narcotic and marihuana laws</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_353_c"><akn:num>(c)</akn:num><akn:heading>Sales restrictions</akn:heading><akn:content><akn:p>(c) Sales restrictions</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_353_d"><akn:num>(d)</akn:num><akn:heading>Distribution of drug samples</akn:heading><akn:content><akn:p>(d) Distribution of drug samples</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_353_e"><akn:num>(e)</akn:num><akn:heading>Licensing and reporting requirements for wholesale distributors; fees; definitions</akn:heading><akn:content><akn:p>(e) Licensing and reporting requirements for wholesale distributors; fees; definitions</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_353_f"><akn:num>(f)</akn:num><akn:heading>Veterinary prescription drugs</akn:heading><akn:content><akn:p>(f) Veterinary prescription drugs</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_353_g"><akn:num>(g)</akn:num><akn:heading>Regulation of combination products</akn:heading><akn:content><akn:p>(g) Regulation of combination products</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_353_ii"><akn:num>(ii)</akn:num><akn:content><akn:p>(ii) A meeting under clause (i) may—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_353_iii"><akn:num>(iii)</akn:num><akn:content><akn:p>(iii) Any agreement under this subparagraph shall be in writing and made part of the administrative record by the Secretary.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_353_iii"><akn:num>(iii)</akn:num><akn:content><akn:p>(iii) The Office shall ensure that, with respect to a combination product, a designated person or persons in the primary agency center is the primary point or points of contact for the sponsor of such combination product. The Office shall also coordinate communications to and from any consulting center involved in such premarket review, if requested by such primary agency center or any such consulting center. Agency communications and commitments, to the extent consistent with other provisions of law and the requirements of all affected agency centers, from the primary agency center shall be considered as communication from the Secretary on behalf of all agency centers involved in the review.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>